
Biogen Inc.: updates and filings
Price
$249.59
November 20, 2026Market cap $36.6B
What Ploutos Investor adds for Biogen
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 28, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
July 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 28, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 28, 2026Results of operationsForm8-K
- Aug 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 29, 2026Results of operationsForm8-K
- Jul 1, 2026Results of operationsForm8-K
- Jun 10, 2026Shareholder voteForm8-K
- Jun 10, 2026Financial statements and exhibits (amendment)Form8-K/A
- Jun 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 14, 2026Material agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosureForm8-K
- May 14, 2026Filing (amendment)FormSC TO-T/A
- May 12, 2026AMENDMENT NO. 2 (amendment)FormSC TO-T/A
- May 6, 2026AMENDMENT NO. 1 (amendment)FormSC TO-T/A
- May 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 29, 2026Results of operationsForm8-K
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 14, 2026FilingFormSC TO-T
- Apr 7, 2026SCHEDULE TOFormSC TO-C
- Apr 6, 2026Over-5% holder statement (active)FormSCHEDULE 13D
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 28, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 28, 2026 | 8-K | Results of operations | Document |
| Aug 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 29, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 29, 2026 | 8-K | Results of operations | Document |
| Jul 1, 2026 | 8-K | Results of operations | Document |
| Jun 10, 2026 | 8-K | Shareholder vote | Document |
| Jun 10, 2026 | 8-K/A | Financial statements and exhibits (amendment) | Document |
| Jun 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 14, 2026 | 8-K | Material agreement entered, acquisition or disposal of assets, new material financial obligation, Regulation FD disclosure | Document |
| May 14, 2026 | SC TO-T/A | Filing (amendment) | Document |
| May 12, 2026 | SC TO-T/A | AMENDMENT NO. 2 (amendment) | Document |
| May 6, 2026 | SC TO-T/A | AMENDMENT NO. 1 (amendment) | Document |
| May 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 29, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 14, 2026 | SC TO-T | Filing | Document |
| Apr 7, 2026 | SC TO-C | SCHEDULE TO | Document |
| Apr 6, 2026 | SCHEDULE 13D | Over-5% holder statement (active) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since May 21, 1996: every report, 8-K, meeting and letter. Of its other filings (977 in all), the newest.
The full analysis
What do Biogen's filings show?
The filings are where every one of Biogen's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.